Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cytarabine

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
    • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   41039   clinical trials with a EudraCT protocol, of which   6717   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    141 result(s) found for: Cytarabine. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2015-004896-60 Sponsor Protocol Number: LUMC2015-02 Start Date*: 2015-11-26
    Sponsor Name:Leiden University Medical Center
    Full Title: Decitabine-cytarabine chemotherapy in elderly AML and high risk MDS patients (> 65 years) with high early mortality risk
    Medical condition: Acute myeloid leukemia and high risk myelodysplasia
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000344-42 Sponsor Protocol Number: AG-221-AML-004 Start Date*: 2016-01-21
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemi...
    Medical condition: Treatment of subjects 60 years or older with acute myeloid leukemia (AML) refractory to or relapsed after second- or third-line AML therapy and positive for an isocitrate dehydrogenase 2 (IDH2) mut...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10060558 Acute myeloid leukemia recurrent LLT
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Temporarily Halted) GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Ongoing) BE (Ongoing) AT (Completed) CZ (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003025-28 Sponsor Protocol Number: TUD-RELAX1-070 Start Date*: Information not available in EudraCT
    Sponsor Name:Technische Universität Dresden
    Full Title: Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax
    Medical condition: Patients 18-75 years with acute myeloid leukaemia (AML) at first or second relapse after intensive chemotherapy including allogeneic stem cell transplantation or primary refractory to standard indu...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002345-39 Sponsor Protocol Number: Göteborg University Start Date*: 2006-02-16
    Sponsor Name:NOPHO NHL-group
    Full Title: B-NHL BFM 04
    Medical condition: B-cell lymphoma or B-ALL in children up to 18 years of age
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000699-24 Sponsor Protocol Number: PHRC2010-03 Start Date*: 2014-10-02
    Sponsor Name:CHU Angers-DAMR
    Full Title: Essai de phase 3 visant à améliorer la survie globale des LAM de l’adulte de 18 à 60 ans en comparant l’idarubicine à forte dose à la daunorubicine à l’induction, la cytarabine à haute-dose et à do...
    Medical condition: Leucémie aiguë myéloïde
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001588-22 Sponsor Protocol Number: AML003 Start Date*: 2019-07-04
    Sponsor Name:Rafael Pharmaceuticals, Inc.
    Full Title: Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mi...
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) DE (Ongoing) FR (Ongoing) AT (Ongoing) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002822-19 Sponsor Protocol Number: B1371019 Start Date*: 2018-07-09
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN ...
    Medical condition: ACUTE MYELOID LEUKEMIA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) CZ (Ongoing) SE (Completed) BE (Ongoing) PL (Ongoing) ES (Ongoing) DE (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-005794-29 Sponsor Protocol Number: GFM-BAR-C-2005 Start Date*: 2006-03-30
    Sponsor Name:Groupe français des Myélodysplasies
    Full Title: Traitement des syndromes myélodysplasiques par l'association aracytine et bortezomib
    Medical condition: Myelodysplastic syndrome (MDS) is a clonal disease of the bone marrow stem cells. The disease is frequently associated with cytopenia and/or blastosis. An evolution to an acute leukemia is not unfr...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023691-33 Sponsor Protocol Number: MUV-MEMMAT-01 Start Date*: 2011-05-05
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Kinder- und Jugendheilkunde
    Full Title: A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma, ependymoma and ATRT
    Medical condition: Recurrent/progressive medulloblastoma, ependymoma and ATRT
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Ongoing) SE (Restarted) CZ (Ongoing) DK (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003031-19 Sponsor Protocol Number: IELSG42 Start Date*: 2014-12-15
    Sponsor Name:IELSG (INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP)
    Full Title: An international phase II trial assessing tolerability and efficacy of sequential Methotrexate-Aracytin-based combination and R-ICE combination, followed by high-dose chemotherapy supported by auto...
    Medical condition: systemic diffuse large B-cell lymphoma with central nervous system involvement at diagnosis or relapse
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014462-26 Sponsor Protocol Number: DB-AML-01 Start Date*: 2010-05-04
    Sponsor Name:Ghent University Hospital
    Full Title: Dutch-Belgian pediatric AML protocol for children with newly diagnosed acute myeloid leukemia, based on the NOPHO-AML 2004 study
    Medical condition: Acute Myeloid Leukemia in children
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012432-32 Sponsor Protocol Number: IELSG 32 Start Date*: 2010-03-25
    Sponsor Name:IELSG-International Extranodal Lymphoma Study Group
    Full Title: Randomized phase II trial on primary chemotherapy with high-dose methotrexate and high-dose cytarabine with or without thiotepa, and with or without rituximab, followed by brain irradiation vs. h...
    Medical condition: newly diagnosed primary CNS lymphoma in immunocompetent patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036685 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) DE (Ongoing) GB (GB - no longer in EU/EEA) DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001201-24 Sponsor Protocol Number: KRT-232-104 Start Date*: 2019-12-02
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML).
    Medical condition: Relapsed or refractory AML, AML secondary to myeloproliferative neoplasms (MPN), and JAK2 mutationpositive AML.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Ongoing) GB (GB - no longer in EU/EEA) HU (Ongoing) PL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012758-18 Sponsor Protocol Number: COALL09-05-04 Start Date*: 2010-09-09
    Sponsor Name:Universitätsklinikum Hamburg-Eppendorf
    Full Title: A randomized multi-center treatment study (COALL 08-09) to improve the survival of children with acute lymphoblastic leukemia on behalf of the German Society of Pediatric Hematology and Oncology
    Medical condition: acute lymphoblastic leukemia in children and adolescents 1 to ≤ 18 years of age
    Disease: Version SOC Term Classification Code Term Level
    12.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000279-16 Sponsor Protocol Number: TRALG 1/02 Start Date*: 2007-06-07
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: Phase III Clinical Study of Allogeneic Stem Cell Transplantation with Reduced Conditioning (RICT) versus Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission
    Medical condition: Acute myeloid leukemia in first complete remission
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010951-28 Sponsor Protocol Number: CLTR0308-205 Start Date*: 2009-09-30
    Sponsor Name:Celator Pharmaceuticals, Inc
    Full Title: Phase IIB, multicenter, randomized, open-label trial of CPX-351 (Cytarabine:Daunorubicin) liposome injection versus intensive salvage therapy in adult patients ≤ 60 years old with AML in first rela...
    Medical condition: Acute myeloid leukemia recurrent (Acute Myeloid Leukemia in First Relapse Following an Initial CR >1 Month Duration).
    Disease: Version SOC Term Classification Code Term Level
    12.0 10060558 Acute myeloid leukemia recurrent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002675-17 Sponsor Protocol Number: NCT-2017-0545 Start Date*: 2019-12-20
    Sponsor Name:Ruprecht-Karls-University of Heidelberg Medical Faculty represented in law by Heidelberg University Hospital
    Full Title: Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD
    Medical condition: Relapsed/Refractory AML with FLT3-ITD
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004421-24 Sponsor Protocol Number: LUMC2012-02 Start Date*: 2014-04-14
    Sponsor Name:Leiden Universtity Medical Center
    Full Title: Sequential FLAMSA chemotherapy and T cell depleted reduced intensity conditioning allogeneic stem cell transplantation (TCD FLAMSA-RIC alloSCT) in elderly acute myeloid leukemia and high risk myelo...
    Medical condition: acute myeloid leukemia and high risk myelodysplasia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004893-28 Sponsor Protocol Number: CLAMYIIFF Start Date*: 2012-03-13
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA O.I.R.M. - S. ANNA
    Full Title: PHASE II STUDY OF CLOFARABINE IN COMBINATION WITH CYTARABINE AND LIPOSOMAL DOXORUBICIN IN CHILDREN WITH EITHER LYMPHOBLASTIC OR MYELOID RELAPSE OR REFRACTORY ACUTE LEUKEMIA AND IN CHILDREN WITH SEC...
    Medical condition: RELAPSED/REFRACTORY PEDIATRIC ACUTE EITHER LYMPHOBLASTIC OR MYELOID LEUKEMIA AND SECONDARY ACUTE MYELOID LEUKEMIA.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060356 Acute myeloid leukaemia without mention of remission LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059034 Acute myeloid leukaemia recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060352 Acute lymphoid leukaemia without mention of remission LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063621 Acute lymphoblastic leukaemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-005158-12 Sponsor Protocol Number: NCT-2017-0530 Start Date*: 2019-04-01
    Sponsor Name: Ruprecht-Karls-University Heidelberg Medical Faculty, University Hospital
    Full Title: TEAM-Trial: Targeting Epigenetic therapy resistance in AML with Bortezomib: A multi-centre matched threshold crossing phase II approach
    Medical condition: Patients with confirmed diagnosis of Acute Myeloid Leukemia (AML)according to WHO-2016 classification (except acute promyelocytic leukemia) either de novo AML, AML after preceding myelodysplastic o...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands     Legal notice
    EMA HMA